Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma

被引：55

作者：

Hicks, L. K. ^{[2
,6
]}

Woods, A. ^{[3
]}

Buckstein, R. ^{[1
,6
]}

Mangel, J. ^{[4
]}

Pennell, N. ^{[1
]}

Zhang, L. ^{[1
]}

Imrie, K. ^{[1
,6
]}

Spaner, D. ^{[1
,6
]}

Cheung, M. C. ^{[1
,6
]}

Boudreau, A. ^{[1
]}

Reis, M. ^{[1
,6
]}

Crump, M. ^{[5
,6
]}

Berinstein, N. L. ^{[1
,6
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Adv Therapeut Program, Toronto, ON M4N 3M5, Canada

[2] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada

[3] Univ Alberta, Dept Med, Edmonton, AB, Canada

[4] Univ Western Ontario, Dept Med, London Reg Canc Ctr, London, ON, Canada

[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[6] Univ Toronto, Dept Med, Toronto, ON, Canada

来源：

BONE MARROW TRANSPLANTATION | 2009年 / 43卷 / 09期

基金：

加拿大健康研究院;

关键词：

follicular lymphoma; rituximab; auto-SCT; minimal residual disease; hypogammaglobulinemia; NON-HODGKINS-LYMPHOMA; AUTOLOGOUS BONE-MARROW; STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; POLYMERASE-CHAIN-REACTION; MONOCLONAL-ANTIBODY THERAPY; MINIMAL RESIDUAL DISEASE; FOLLOW-UP; PROGNOSTIC-FACTORS; SEQUENTIAL CHEMOTHERAPY;

D O I：

10.1038/bmt.2008.382

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

We enrolled 23 patients with relapsed follicular lymphoma (FL) in a prospective single-arm study of auto-SCT combined with in vivo rituximab graft purging and post transplant rituximab maintenance. Minimal residual disease was monitored with quantitative PCR testing. With a median follow-up of 74.2 months, neither median overall survival (OS) nor PFS has been reached. Here, 5-year OS and 5-year PFS are 78% (95% confidence interval (CI) 61-95%) and 59% ( 95% CI 38-80%), respectively. Time to progression (TTP) with the experimental regimen was significantly improved compared with TTP with the last prior treatment (P<0.001). Durable molecular remissions occurred in 11 of 13 assessable patients. PFS was significantly longer in patients who achieved a molecular remission by 3 months post-auto-SCT (P = 0.001). Prolonged hypogammaglobulinemia occurred in most patients; however, no increase in major infections was observed. Bone Marrow Transplantation (2009) 43, 701-708; doi:10.1038/bmt.2008.382; published online 24 November 2008

引用

页码：701 / 708

页数：8

共 62 条

[21] Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes [J].

Corradini, P ;

Ladetto, M ;

Zallio, F ;

Astolfi, M ;

Rizzo, E ;

Sametti, S ;

Cuttica, A ;

Rosato, R ;

Farina, L ;

Boccadoro, M ;

Benedetti, F ;

Pileri, A ;

Tarella, C .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1460-1468

[22] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

[23] GENETIC MARKING SHOWS THAT PH(+) CELLS PRESENT IN AUTOLOGOUS TRANSPLANTS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) CONTRIBUTE TO RELAPSE AFTER AUTOLOGOUS BONE-MARROW IN CML [J].

DEISSEROTH, AB ;

ZU, ZF ;

CLAXTON, D ;

HANANIA, EG ;

FU, SQ ;

ELLERSON, D ;

GOLDBERG, L ;

THOMAS, M ;

JANICEK, K ;

ANDERSON, WF ;

HESTER, J ;

KORBLING, M ;

DURETT, A ;

MOEN, R ;

BERENSON, R ;

HEIMFELD, S ;

HAMER, J ;

CALVERT, L ;

TIBBITS, P ;

TALPAZ, M ;

KANTARJIAN, H ;

CHAMPLIN, R ;

READING, C .

BLOOD, 1994, 83 (10) :3068-3076

[24] New treatment options have changed the survival of patients with follicular lymphoma [J].

Fisher, RI ;

LeBlanc, M ;

Press, OW ;

Maloney, DG ;

Unger, JM ;

Miller, TP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8447-8452

[25] The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J].

Forstpointner, R ;

Dreyling, M ;

Repp, R ;

Hermann, S ;

Hänel, A ;

Metzner, B ;

Pott, C ;

Hartmann, F ;

Rothmann, F ;

Rohrberg, R ;

Böck, HP ;

Wandt, H ;

Unterhalt, M ;

Hiddemann, W .

BLOOD, 2004, 104 (10) :3064-3071

[26] Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [J].

Freedman, AS ;

Neuberg, D ;

Mauch, P ;

Soiffer, RJ ;

Anderson, KC ;

Fisher, DC ;

Schlossman, R ;

Alyea, EP ;

Takvorian, T ;

Jallow, H ;

Kuhlman, C ;

Ritz, J ;

Nader, LM ;

Gribben, JG .

BLOOD, 1999, 94 (10) :3325-3333

[27] Quantitative molecular evaluation in autotransplant programs for follicular lymphoma:: efficacy of in vivo purging by Rituximab [J].

Galimberti, S ;

Guerrini, F ;

Morabito, F ;

Palumbo, GA ;

Di Raimondo, F ;

Papineschi, F ;

Caracciolo, F ;

Fazzi, R ;

Cervetti, G ;

Cuzzocrea, A ;

Petrini, M .

BONE MARROW TRANSPLANTATION, 2003, 32 (01) :57-63

[28] Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation [J].

Girouard, C ;

Dufresne, J ;

Imrie, K ;

Stewart, AK ;

Brandwein, J ;

Prince, HM ;

Pantolony, D ;

Keating, A ;

Crump, M .

ANNALS OF ONCOLOGY, 1997, 8 (07) :675-680

[29] Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab [J].

Goldberg, SL ;

Pecora, AL ;

Alter, RS ;

Kroll, MS ;

Rowley, SD ;

Waintraub, SE ;

Imrit, K ;

Preti, RA .

BLOOD, 2002, 99 (04) :1486-1488

[30]

GRIBBEN JG, 1993, BLOOD, V81, P3449

← 1 2 3 4 5 6 7 →